Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinoma.

  PMID 41923630 · PMC13130666 · Cell reports. Medicine · 2026 · 8 claims · 4 setups

  Full-text index only

  A malignant cell subset expressing IFN-response and MHC-II genes (IFN/MHC-II) increases in proportion after pembrolizumab treatment and is associated with response

  hnscc ffpe syngeneic independent single-cell multiplexed tumor

• Proteomic and genetic approaches identify Syk as an AML target.

  PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups

  Full-text index only

  EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism

  hl-60 aml molm-14 luciferase-labeled phospho-tyrosine kinome-wide secondary

• Reinvigorating COTL1(high) NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours.

  PMID 41912896 · PMC13179135 · Nature cell biology · 2026 · 8 claims · 8 setups

  Full-text index only

  A COTL1-high NK cell subset mediates immune checkpoint blockade responsiveness in tsMHC-I impaired tumours

  hcc sorted orthotopic multiplex bulk single-cell

• PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma.

  PMID 41916996 · PMC13199584 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Non-responders to TKI±ICI therapy show increased neutrophil infiltration and enrichment of SAA+ tumor cells after treatment.

  arcc pre post-treatment tumor single-cell multiplex ligand-receptor

• Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

  PMID 41986344 · PMC13083995 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  BRAFi (vemurafenib) treatment drives BRAF-mutant melanoma cells through a reversible dedifferentiation transition from a melanocytic state through a neural crest-like state to a drug-tolerant mesenchymal state

  m397 patient-derived longitudinal time-series atac-seq chip-seq

• Bacillus Calmette-Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer.

  PMID 35311085 · PMC8930202 · Frontiers in oncology · 2022 · 8 claims · 8 setups

  Has reproduction · 30

  BCG therapy has bidirectional effects on tumor evolution and immune checkpoint landscape, with a significant reduction in neoantigen burden percentage in relapsed tumors

  tur matched nmibc relapsed whole-exome sequencing immune

• Enabling Single-Cell Drug Response Annotations from Bulk RNA-Seq Using SCAD.

  PMID 36762572 · PMC10104628 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023 · 7 claims · 7 setups

  Has reproduction · 81

  SCAD, a transfer learning framework integrating adversarial discriminative domain adaptation (ADDA), can infer single-cell drug sensitivities by transferring knowledge from bulk RNA-seq pharmacogenomic data (GDSC) to scRNA-seq target domains

  pan-cancer pc9 451lu a375 bulk scrna-seq computational

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor